4.5 Article

Meningococcal serogroup Y emergence in Europe High importance in some European regions in 2012

Journal

HUMAN VACCINES & IMMUNOTHERAPEUTICS
Volume 10, Issue 6, Pages 1725-1728

Publisher

LANDES BIOSCIENCE
DOI: 10.4161/hv.28206

Keywords

epidemiology; Europe; invasive meningococcal disease; serogroup Y; meningococcal vaccines; surveillance

Funding

  1. GlaxoSmithKline
  2. Novartis
  3. Pfizer

Ask authors/readers for more resources

Neisseria meningitidis is differentiated into 12 distinct serogroups, of which A, B, C, W, X, and Y are medically most important and represent an important health problem in different parts of the world. The epidemiology of N. meningitidis is unpredictable over time and across geographic regions. Recent epidemiological surveillance has indicated an increase of serogroup Y invasive meningococcal disease in some parts of Europe as shown in the epidemiological data for 2010 and 2011 from various European countries previously published in this journal. 1,2 Here, data from 33 European countries is reported indicating that the emergence of serogroup Y continued in 2012 in various regions of Europe, especially in Scandinavia, while in Eastern and South-Eastern Europe the importance of serogroup Y remained low.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available